Fulgram - Ciprofloxacin is a drug used to treat bacterial infections. It is a second generation fluoroquinolone antibacterial. It kills bacteria by interfering with the enzymes that cause DNA to rewind after being copied, which stops DNA and protein synthesis.
Ciprofloxacin is marketed worldwide with over three hundred different brand names. In the United States, Canada and the UK, it is marketed as Ciloxan, Cipro, Cipro XR, Cipro XL Ciproxin and, most recently, Proquin. In Mexico it is available over the counter and marketed under the names Ciproflox or Ciprofloxacino. In Ecuador it is available and marketed under the name Cidrax. In Nigeria it is sold as Ciprotab while in Bangladesh it is marketed as Tablets and Microcapsules for Suspension by numerous companies, one of which is by Edruc Limited as Cipron. Additionally, ciprofloxacin is available as a generic drug under a variety of different brand names and is also available for limited use in veterinary medicine.
Ciprofloxacin was first patented in 1983 by Bayer A.G. and subsequently approved by the United States Food and Drug Administration (FDA) in 1987.Ciprofloxacin has 12 F.D.A.-approved human uses and other veterinary uses, but it is often used for non-approved uses (off-label).
Ciprofloxacin interacts with other drugs, herbal and natural supplements, and thyroid medications.
Fulgram is an antibiotic. It is used to treat certain bacterial infections of the nose, lungs, skin, bones, joints, genitals, bladder and the digestive system. Fulgram is also used to treat certain sexually transmitted diseases (STD). Fulgram belongs to a group of antibiotics called the quinolones.
Indications: bacterial infections
Indications: urinary-tract infections
Upper and lower, complicated and uncomplicated, acute and chronic urinary tract infections. Prostatitis. Bacterial gastroenteritis. Typhiod fever. Prophylaxis of sepsis in patients with neutropenia. Gonococcal urethritis, proctitis and cervicitis.
This medicine is indicated in the treatment of infections caused by susceptible strains of the designated organisms in the conditions listed below:Lower Respiratory Tract Infections – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Otitis Media – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Sinusitis – caused by β-lactamase–producing strains of H. influenzae and M. catarrhalis. Skin and Skin Structure Infections – caused by β-lactamase–producing strains of S. aureus, E. coli, and Klebsiella spp. Urinary Tract Infections – caused by β-lactamase–producing strains of E. coli, Klebsiella spp., and Enterobacter spp.
Indications: Urinary tract infections.
Bone, soft tissue, gynaecological and wound infections.